Multiarm, nonrandomized, open-label phase IB study to evaluate FP1039/GSK3052230 with chemotherapy in NSCLC and MPM with deregulated FGF pathway signaling.
Pilar Garrido(Hospital Universitario Ramón y Cajal), Ulrik Lassen(Rigshospitalet), Hendrik‐Tobias Arkenau(Sarah Cannon Research Institute), Shirish M. Gadgeel(Chinese University of Hong Kong), Jean‐Pierre Delord, Ignacio Delgado(Universitat Autònoma de Barcelona), Daniel Morgensztern(Barnes-Jewish Hospital), E. Levchenko(Research Medical Center), Karen L. Reckamp(Memorial Sloan Kettering Cancer Center), Luis Paz‐Ares(Hospital Universitario 12 De Octubre), Juneko E. Grilley‐Olson(University of North Carolina at Chapel Hill), Michael S. Gordon(Pinnacle Oncology Hematology), Primo N. Lara(UC Davis Comprehensive Cancer Center), Fabrice Barlési(Hôpital Nord), Erin M. Bertino(The Ohio State University), Enriqueta Felip(Institut Català d'Ornitologia), José M. Pérez(Hospital Clínico Universitario Virgen de la Victoria), Paul K. Paik(Memorial Sloan Kettering Cancer Center), Teresa Morán(Institute of Agrifood Research and Technology), Sergey Orlov(St Petersburg University)
Cited by 4
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Lung cancer: current therapies and new targeted treatments
|The Lancet|2016|3.3k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k